- Financing led by Deep Track Capital with participation from other leading healthcare investors
- Pro-forma cash and cash equivalents of approximately $236 million before fees and expenses
- On track for regulatory filing for First-in-Human (FIH) study of KRRO-110 in Alpha-1 Antitrypsin Deficiency (AATD) patients anticipated in the second half of 2024
- Proceeds fund interim readout in the second half of 2025 and FIH study completion in 2026 for KRRO-110